...
首页> 外文期刊>Journal of nanomaterials >Synthesis, Characterization, and In Vitro Drug Delivery of Chitosan-Silica Hybrid Microspheres for Bone Tissue Engineering
【24h】

Synthesis, Characterization, and In Vitro Drug Delivery of Chitosan-Silica Hybrid Microspheres for Bone Tissue Engineering

机译:壳聚糖 - 二氧化硅杂交微球对骨组织工程的合成,表征和体外药物递送

获取原文

摘要

Chitosan-silica (CS-SiO2) hybrid microspheres were prepared through the combined process of sol-gel and emulsification-crosslinking. Their composition, morphology, in vitro bioactivity, and drug release behavior were investigated. The results showed that, when 20?wt% SiO2 was incorporated, the as-prepared CS-SiO2 hybrid microspheres exhibited a regular spherical shape, a high dispersity, and a uniform microstructure. Their average particle diameter was determined to be about 24.0?μm. The in situ deposited inorganic phase of the hybrid microspheres was identified as amorphous SiO2, and its actual content was determined by the TG analysis. As compared with the pure chitosan microspheres, the CS-SiO2 hybrid microspheres displayed a greatly improved in vitro bioactivity. Vancomycin hydrochloride (VH) was selected as a model drug. It was demonstrated that the CS-SiO2 hybrid microspheres presented a good capacity for both loading and sustained release of VH. Moreover, the increase of the SiO2 content efficiently slowed down the drug release rate of the CS-SiO2 hybrid microspheres.
机译:通过溶胶 - 凝胶的组合过程和乳化交联制备壳聚糖 - 二氧化硅(CS-SiO 2)杂化微球。研究了它们的组成,形态,体外生物活性和药物释放行为。结果表明,当掺入20μl%SiO 2时,制备的CS-SiO 2杂化微球表现出规则的球形形状,高分子和均匀的微观结构。将它们的平均粒径确定为约24.0μm。杂交微球的原位沉积无机相被鉴定为无定形SiO 2,其实际含量通过Tg分析确定。与纯壳聚糖微球相比,CS-SiO2杂交微球的体外生物活性大大提高。选择盐酸核苷酸(VH)作为模型药物。证明CS-SiO2杂交微球呈现良好的载荷和持续释放VH。此外,SiO2含量的增加有效地减慢了CS-SiO2杂交微球的药物释放速率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号